Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Crinetics Pharmaceuticals, Inc. - Common Stock
(NQ:
CRNX
)
39.69
-0.43 (-1.08%)
Streaming Delayed Price
Updated: 3:54 PM EST, Mar 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Crinetics Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Crinetics (CRNX) Q4 2025 Earnings Call Transcript
↗
February 26, 2026
Crinetics (CRNX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Crinetics Pharmaceuticals (NASDAQ:CRNX) Beats Q4 Revenue Estimates on First Product Sales
↗
February 26, 2026
Via
Chartmill
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology
January 28, 2026
As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused...
Via
Finterra
Topics
Economy
Intellectual Property
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial
↗
January 05, 2026
Via
Stocktwits
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Retail Chatter Surges As Crinetics Wins FDA Nod For First Oral Acromegaly Drug — Traders Expect Big Price Move
↗
September 25, 2025
Via
Stocktwits
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
The market is filled with gapping stocks in Wednesday's session.
↗
January 07, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
January 05, 2026
Via
Chartmill
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year
↗
November 27, 2025
Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.
Via
The Motley Fool
Topics
Regulatory Compliance
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday
↗
November 07, 2025
The company is preparing a rollout of its recently FDA-approved acromegaly treatment.
Via
The Motley Fool
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Emerges as a Technical Breakout Candidate
↗
November 07, 2025
Crinetics Pharmaceuticals (CRNX) shows strong technical momentum and a high-quality consolidation setup, signaling a potential breakout opportunity for traders.
Via
Chartmill
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reports Q3 2025 Earnings Miss
↗
November 06, 2025
Crinetics Q3 2025 earnings miss estimates as it transitions to a commercial-stage company following the U.S. launch of its new drug, PALSONIFY.
Via
Chartmill
Topics
Earnings
Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
October 13, 2025
Via
Benzinga
Is Crinetics Pharmaceuticals Stock a Buy?
↗
September 28, 2025
The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.
Via
The Motley Fool
FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder
↗
September 26, 2025
On Thursday, the U.S.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
September 26, 2025
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
Via
Benzinga
Friday's session: gap up and gap down stocks
↗
September 26, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via
Chartmill
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday
↗
September 26, 2025
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA...
Via
Benzinga
Topics
Stocks
Assessing Crinetics Pharmaceuticals: Insights From 4 Financial Analysts
↗
September 26, 2025
Throughout the last three months, 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: CRNX), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments,...
Via
Benzinga
Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism
↗
September 26, 2025
The company's drug, Palsonify, treats acromegaly, a condition in which the pituitary gland makes too much growth hormone.
Via
Investor's Business Daily
Topics
Artificial Intelligence
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
September 26, 2025
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
Via
Benzinga
Tuesday's pre-market session: top gainers and losers
↗
August 19, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
August 19, 2025
Via
Benzinga
Crinetics (CRNX) Q2 Revenue Jumps 150%
↗
August 07, 2025
Via
The Motley Fool
Topics
Intellectual Property
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly
↗
July 14, 2025
Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients over 84–96 weeks.
Via
Benzinga
Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds
↗
July 13, 2025
The company presented new data at ENDO 2025 showing that patients who switched from monthly injections to the daily pill maintained hormone control and saw fewer symptom flare-ups over nearly two...
Via
Stocktwits
Topics
Government
JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics' Atumelnant Data
↗
March 26, 2025
JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions. Analysts see long-term potential.
Via
Benzinga
Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology
↗
March 25, 2025
Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
